Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Sakar Healthcare's OCF Margin % or its related term are showing as below:
NSE:SAKAR'
s OCF Margin % Range Over the Past 10 Years
Min: 9.92 Med: 19.39 Max: 25
Current: 19.57
During the past 11 years, the highest OCF Margin % of Sakar Healthcare was 25.00%. The lowest was 9.92%. And the median was 19.39%.
NSE:SAKAR's OCF Margin % is ranked better than 76.76% of 964
companies
in the Drug Manufacturers industry
Industry Median: 10.04
vs NSE:SAKAR: 19.57
Sakar Healthcare OCF Margin % Related Terms
Sakar Healthcare OCF Margin % Historical Data
* Premium members only.
The historical data trend for Sakar Healthcare's OCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Sakar Healthcare's OCF Margin %, along with its competitors' market caps and OCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sakar Healthcare OCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sakar Healthcare's OCF Margin % distribution charts can be found below:
* The bar in red indicates where Sakar Healthcare's OCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sakar Healthcare (NSE:SAKAR) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Sakar Healthcare and its competitors. Over the past decade, Sakar Healthcare's OCF Margin % has ranged from 9.92 to 25.00. According to the industry distribution chart, Sakar Healthcare ranks #224 out of 964 companies in the Drug Manufacturers industry, placing it in the top 23.2%.
Is Sakar Healthcare's OCF Margin % too high?
Sakar Healthcare's current OCF Margin % is 0.00%. Over the past 10 years, this metric has ranged from a low of 9.92 to a high of 25.00. Based on the distribution chart, Sakar Healthcare ranks #224 out of 964 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sakar Healthcare has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Sakar Healthcare's OCF Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Sakar Healthcare ranks #224 out of 964 companies for OCF Margin %. This places Sakar Healthcare in the top 23% of its industry — outperforming the majority of peers. The industry median OCF Margin % is 10.04. Historically, Sakar Healthcare's own OCF Margin % has ranged from 9.92 to 25.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Drug Manufacturers company?
The median OCF Margin % among Drug Manufacturers companies is 10.04, based on 964 companies in the industry. Companies in the top quartile (top 25%) have a OCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Sakar Healthcare and its competitors. For the Drug Manufacturers industry, the median OCF Margin % is 10.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sakar Healthcare's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sakar Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Sakar Healthcare (NSE:SAKAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹540.00, compared to a current price of ₹904.45 — trading 67.5% above its estimated fair value. The current OCF Margin % is 0.00%. Sakar Healthcare's overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Sakar Healthcare (NSE:SAKAR), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sakar Healthcare (NSE:SAKAR) Overvalued in 2026?
Based on GuruFocus' analysis, Sakar Healthcare stock appears to be overvalued.
The current stock price of ₹904.45 is trading 67.5% above its estimated GF Value™ of ₹540.00.
GuruFocus considers Sakar Healthcare to be Significantly Overvalued.
Key valuation signals for NSE:SAKAR:
OCF Margin %: 0.00%
GF Value™: ₹540.00 vs. price of ₹904.45 (67.5% above fair value)
No single metric tells the full story. See the NSE:SAKAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sakar Healthcare Ltd is engaged in manufacturing Pharmaceutical products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections. The company offers its products to Sri Lanka, the Philippines, Vietnam, Cambodia, Sudan, Myanmar, Mauritius, Costa Rica, Panama, El Salvador and Paraguay.
60GF Score
Get the complete analysis for NSE:SAKAR
OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAKAR has been successfully added to your 
